Cardiovascular Systems Stock
Your prediction
Pros and Cons of Cardiovascular Systems in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cardiovascular Systems vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cardiovascular Systems | - | - | - | - | - | - | - |
| Lantheus Holdings Inc | -3.660% | -1.530% | -6.535% | 44.160% | 57.517% | 12.936% | - |
| Natera Inc | 0.680% | -5.586% | -3.445% | 84.500% | 12.386% | 417.290% | 135.532% |
| Orasure Tech | 1.160% | 5.488% | -8.466% | 20.979% | 67.961% | -17.225% | -60.842% |
News
Boston Scientific Q2 Earnings Call Highlights
Key Points
- Interested in Boston Scientific Corporation? Here are five stocks we like better.
- Strong Q2 results, lower outlook: Boston Scientific posted 7% organic revenue growth and adjusted EPS
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
Key Points
- Interested in BioAge Labs, Inc.? Here are five stocks we like better.
- BioAge Labs said its lead drug BGE-102 is on track for near-term data in two areas: a Phase 2 cardiovascular
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing